Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043069 · ClinicalTrials.gov registry record · Phase 3
Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 71
- Enrollment target
NCT00043069 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 71 participants.
The verdict
NCT00043069, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 71 participants
- Enrollment target
Study Summary
RATIONALE: Preventing bone loss in patients who are undergoing androgen ablation for prostate cancer may decrease the risk of fractures and may help patients live more comfortably. It is not yet known whether calcium is more effective with or without estrogen and/or risedronate in preventing osteoporosis. PURPOSE: Randomized phase III trial to compare the effectiveness of two forms of calcium with or without estrogen and/or risedronate in preventing osteoporosis in patients with prostate cancer who are receiving androgen ablation therapy.
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT cholecalciferol
- DIETARY_SUPPLEMENT calcium carbonate
- DRUG risedronate sodium
- DRUG Estrogen Antagonists
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2002-11 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043069
The ClinicalTrials.gov registry entry for NCT00043069 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT00043069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00043069 about?
NCT00043069 is a clinical study titled "Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer". RATIONALE: Preventing bone loss in patients who are undergoing androgen ablation for prostate cancer may decrease the risk of fractures and may help patients live more comfortably. It is not yet known whether calcium is more effective with or without estrogen and/or risedronate in preventing osteopo...
What is the current status of trial NCT00043069?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 71 participants. The study started on 2002-11. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00043069?
The interventions under investigation include: placebo (OTHER), cholecalciferol (DIETARY_SUPPLEMENT), calcium carbonate (DIETARY_SUPPLEMENT), risedronate sodium (DRUG), Estrogen Antagonists (DRUG).
Who is sponsoring clinical trial NCT00043069?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.